Therapeutic areas

We’re harnessing our deep knowledge of inflammatory mechanisms and the science of the immune system to redefine the future of respiratory medicine and target lung, liver and kidney disease.

We’re expanding rapidly beyond our focus in blood and gynecological cancers into lung and gastrointestinal cancers, prostate cancers, and other solid tumours.

We’re leaders in HIV, focused on ending the global epidemic. We have an industry-leading pipeline, driven by patient insights.

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.